Adalat and Alimta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Adalat (nifedipine) and Alimta (pemetrexed disodium). Common drug interactions include cholestasis among females and platelet count decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Adalat and Alimta. It is created by eHealthMe based on reports of 23 people who take the same drugs from the FDA, and is updated regularly.

What is Adalat?

Adalat has active ingredients of nifedipine. It is often used in high blood pressure. eHealthMe is studying from 20,940 Adalat users. Check the latest studies of Adalat.

What is Alimta?

Alimta has active ingredients of pemetrexed disodium. eHealthMe is studying from 7,702 Alimta users. Check the latest studies of Alimta.

On Jul, 12, 2026

23 people who take Adalat and Alimta together, and have interactions are studied.

What are the common drug interactions of Adalat and Alimta, by gender? *:

female:

Cholestasis (a condition where bile cannot flow from the liver to the duodenum)
Liver injury
Gamma-glutamyltransferase increased
Transaminases increased
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Renal disorder (kidney disease)
Anaemia (lack of blood)
C-reactive protein increased
Diarrhoea
Disseminated intravascular coagulation (systemic activation of blood coagulation)

male:

Platelet count decreased
Blood creatinine increased
Tendon rupture (tear of tendon)
Tendonitis (a condition that causes pain and swelling of tendons)
Asthenia (weakness)
Gastritis haemorrhagic (inflammation of stomach with bleeding)
Gastrointestinal perforation (hole in the digestive tract)
Hypokalaemia (low potassium)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs)

What are the common drug interactions of Adalat and Alimta, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Blood creatinine increased
Conjunctival hyperaemia (congestion of conjunctival vessels)
Constipation
Erythema (redness of the skin)
Hyperuricaemia (level of uric acid in the blood that is abnormally high)
Insomnia (sleeplessness)
Neutropenic infection (infection with less neutrophil numbers in blood)
Platelet count decreased
Pyrexia (fever)
Tendon rupture (tear of tendon)

50-59:

n/a

60+:

Interstitial lung disease
Transaminases increased
C-reactive protein increased
Disseminated intravascular coagulation (systemic activation of blood coagulation)
Gastritis haemorrhagic (inflammation of stomach with bleeding)
Granulocyte count decreased
Hypokalaemia (low potassium)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Infection
Pyrexia (fever)

What are the existing conditions these people have? *

Lung Adenocarcinoma Stage Iii (the cancer has spread to nearby tissue or too far away lymph nodes): 6 people, 26.09%
Constipation: 5 people, 21.74%
Lung Cancer - Non-Small Cell (lung cancer): 4 people, 17.39%
Lung Adenocarcinoma Metastatic (a form of non-small cell lung cancer spreads to other part): 4 people, 17.39%
Insomnia (sleeplessness): 4 people, 17.39%
Lung Neoplasm Malignant (cancer tumour of lung): 3 people, 13.04%
Fever: 3 people, 13.04%
Pain: 2 people, 8.70%
Dyslipidaemia (abnormal amount of lipids): 2 people, 8.70%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 2 people, 8.70%

* Approximation only. Some reports may have incomplete information.

Do you take Adalat and Alimta?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously